Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway

Overview

Journal Front Pharmacol

Date 2021 Dec 6

PMID 34867394

Citations 8

Authors

Abraham Tettey

Yujie Jiang

Xiaohui Li

Ying Li

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) is a severe disease with a resultant increase of the mean pulmonary arterial pressure, right ventricular hypertrophy and eventual death. Research in recent years has produced various therapeutic options for its clinical management but the high mortality even under treatment remains a big challenge attributed to the complex pathophysiology. Studies from clinical and non-clinical experiments have revealed that the nitric oxide (NO) pathway is one of the key pathways underlying the pathophysiology of PAH. Many of the essential drugs used in the management of PAH act on this pathway highlighting its significant role in PAH. Meanwhile, several novel compounds targeting on NO pathway exhibits great potential to become future therapy medications. Furthermore, the NO pathway is found to interact with other crucial pathways. Understanding such interactions could be helpful in the discovery of new drug that provide better clinical outcomes.

Citing Articles

Endothelial Function in Pulmonary Arterial Hypertension: From Bench to Bedside.

Correale M, Chirivi F, Bevere E, Tricarico L, DAlto M, Badagliacca R J Clin Med. 2024; 13(8).

PMID: 38673717 PMC: 11051060. DOI: 10.3390/jcm13082444.

An Unusual Etiology of Severe Right Heart Failure Deserving of Wider Recognition.

Kang W, Zong Y, Patel D, Mishra T, Afonso L JACC Case Rep. 2024; 29(5):102222.

PMID: 38464798 PMC: 10920146. DOI: 10.1016/j.jaccas.2024.102222.

Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization.

Salvatori L, Malatesta S, Illi B, Somma M, Fionda C, Stabile H Int J Mol Sci. 2023; 24(14).

PMID: 37511047 PMC: 10379318. DOI: 10.3390/ijms241411286.

Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future.

Fike C, Aschner J Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111262 PMC: 10141152. DOI: 10.3390/ph16040503.

Role of ryanodine receptor 2 and FK506-binding protein 12.6 dissociation in pulmonary hypertension.

Wang Y, Reyes-Garcia J, Di Mise A, Zheng Y J Gen Physiol. 2023; 155(3.

PMID: 36625865 PMC: 9836826. DOI: 10.1085/jgp.202213100.

References

Vane J, Corin R . Prostacyclin: a vascular mediator. Eur J Vasc Endovasc Surg. 2003; 26(6):571-8. DOI: 10.1016/s1078-5884(03)00385-x. View

Cogolludo A, Perez-Vizcaino F, Ibarra M, Lopez-Lopez G, Lopez-Miranda V, Tamargo J . Mechanisms involved in SNP-induced relaxation and [Ca+]i reduction in piglet pulmonary and systemic arteries. Br J Pharmacol. 2001; 132(4):959-67. PMC: 1572630. DOI: 10.1038/sj.bjp.0703894. View

Chandra S, Razavi H, Kim J, Agrawal R, Kundu R, De Jesus Perez V . Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2011; 31(4):814-20. PMC: 3113525. DOI: 10.1161/ATVBAHA.110.219980. View

Rubin L, Badesch D, Fleming T, Galie N, Simonneau G, Ghofrani H . Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011; 140(5):1274-1283. DOI: 10.1378/chest.10-0969. View

Rosenkranz S . Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options. Clin Res Cardiol. 2014; 104(3):197-207. DOI: 10.1007/s00392-014-0765-4. View

Millatt L, Whitley G, Li D, Leiper J, Siragy H, Carey R . Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation. 2003; 108(12):1493-8. DOI: 10.1161/01.CIR.0000089087.25930.FF. View

Arjona A, Hsu C, Wrenn D, Hill N . Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds. Gen Pharmacol. 1997; 28(3):387-92. DOI: 10.1016/s0306-3623(96)00275-3. View

Kharitonov S, Cailes J, Black C, du Bois R, Barnes P . Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax. 1998; 52(12):1051-5. PMC: 1758461. DOI: 10.1136/thx.52.12.1051. View

Mondejar-Parreno G, Moral-Sanz J, Barreira B, de la Cruz A, Gonzalez T, Callejo M . Activation of K 7 channels as a novel mechanism for NO/cGMP-induced pulmonary vasodilation. Br J Pharmacol. 2019; 176(13):2131-2145. PMC: 6555858. DOI: 10.1111/bph.14662. View

10.

Liu Y, Tian X, Mao G, Fang X, Fung M, Shyy J . Peroxisome proliferator-activated receptor-γ ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor. Hypertension. 2012; 60(6):1471-8. DOI: 10.1161/HYPERTENSIONAHA.112.198887. View

11.

Dai G, Li B, Xu Y, Zeng Z, Yang H . Oxymatrine prevents the development of monocrotaline-induced pulmonary hypertension via regulation of the N, N-dimethyl-L-arginine metabolism pathways in rats. Eur J Pharmacol. 2018; 842:338-344. DOI: 10.1016/j.ejphar.2018.11.007. View

12.

Yang P, Read C, Kuc R, Nyimanu D, Williams T, Crosby A . A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. Br J Pharmacol. 2019; 176(9):1206-1221. PMC: 6468262. DOI: 10.1111/bph.14603. View

13.

Wang D, Li H, Weir E, Xu Y, Xu D, Chen Y . Dimethylarginine dimethylaminohydrolase 1 deficiency aggravates monocrotaline-induced pulmonary oxidative stress, pulmonary arterial hypertension and right heart failure in rats. Int J Cardiol. 2019; 295:14-20. DOI: 10.1016/j.ijcard.2019.07.078. View

14.

Zhang R, Wang X, Zhang H, Sun X, Zhao Q, Wang L . Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2016; 48(5):1386-1395. DOI: 10.1183/13993003.00245-2016. View

15.

Jing Z, Yu Z, Shen J, Wu B, Xu K, Zhu X . Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011; 183(12):1723-9. DOI: 10.1164/rccm.201101-0093OC. View

16.

Jackson W . K channels and the regulation of vascular smooth muscle tone. Microcirculation. 2017; 25(1). PMC: 5760307. DOI: 10.1111/micc.12421. View

17.

Malinovschi A, Henrohn D, Eriksson A, Lundberg J, Alving K, Wikstrom G . Increased plasma and salivary nitrite and decreased bronchial contribution to exhaled NO in pulmonary arterial hypertension. Eur J Clin Invest. 2011; 41(8):889-97. DOI: 10.1111/j.1365-2362.2011.02488.x. View

18.

Zakrzewicz D, Eickelberg O . From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases. BMC Pulm Med. 2009; 9:5. PMC: 2637832. DOI: 10.1186/1471-2466-9-5. View

19.

Chang H, Song S, Chang S, Kim H, Jung H, Choi J . Efficacy and Safety of Udenafil for the Treatment of Pulmonary Arterial Hypertension: a Placebo-controlled, Double-blind, Phase IIb Clinical Trial. Clin Ther. 2019; 41(8):1499-1507. DOI: 10.1016/j.clinthera.2019.05.006. View

20.

Simonneau G, Rubin L, Galie N, Barst R, Fleming T, Frost A . Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2014; 33(7):689-97. DOI: 10.1016/j.healun.2014.02.019. View